FDA Approves Bosutinib for Children With CML FDA Approves Bosutinib for Children With CML
The agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer & Oncology | Children | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Pediatrics